Evidence map›Paper›PMID 29230878›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2018

A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia.

M Reddy, N Jugnee, A El Laboudi, E Spanudakis, S Anantharaja, N Oliver

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03028220 (Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous), which is not on this map. Cited by 103 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03028220 nacompletednot on this map

Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous

TypeinterventionalSponsorImperial College LondonRan2016 to 2017Enrolled40ConditionsType 1 Diabetes Mellitus With Hypoglycemia, Impaired Awareness of Hypoglycemia, Type1diabetesArmsDexcom G5 Continuous Glucose Monitor, Abbott Freestyle Libre
3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. A Randomized Study of theJournal of the Endocrine Society · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. The impact of technology on impaired awareness of hypoglycaemia in type 1 diabetes.Therapeutic advances in endocrinology and metabolism · 2025
    Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

M ReddyDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.
N JugneeDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.
A El LaboudiDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.
E SpanudakisDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.
S AnantharajaDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.
N OliverDivision of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, London, UK.ORCID 0000-0003-3525-3633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimHypoglycaemia in Type 1 diabetes is associated with mortality and morbidity, especially where awareness of hypoglycaemia is impaired. Clinical pathways for access to continuous glucose monitoring (CGM) and flash glucose monitoring technologies are unclear. We assessed the impact of CGM and flash glucose monitoring in a high-risk group of people with Type 1 diabetes.

methodsA randomized, non-masked parallel group study was undertaken. Adults with Type 1 diabetes using a multiple-dose insulin-injection regimen with a Gold score of ≥ 4 or recent severe hypoglycaemia were recruited. Following 2 weeks of blinded CGM, they were randomly assigned to CGM (Dexcom G5) or flash glucose monitoring (Abbott Freestyle Libre) for 8 weeks. The primary outcome was the difference in time spent in hypoglycaemia (below 3.3 mmol/l) from baseline to endpoint with CGM versus flash glucose monitoring.

resultsSome 40 participants were randomized to CGM (n = 20) or flash glucose monitoring (n = 20). The participants (24 men, 16 women) had a median (IQR) age of 49.6 (37.5-63.5) years, duration of diabetes of 30.0 (21.0-36.5) years and HbA

conclusionCGM more effectively reduces time spent in hypoglycaemia in people with Type 1 diabetes and impaired awareness of hypoglycaemia compared with flash glucose monitoring. (Clinical Trial Registry No: NCT03028220).

Indexed as

AdultAwarenessBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansHypoglycemiaMaleMiddle AgedPerceptionPilot ProjectsTreatment OutcomeBlood GlucoseGlycated Hemoglobin

Identifiers

PMID29230878
PMCPMC5888121

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.